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Adiponectin in renal disease: Relationship to phenotype and
genetic variation in the gene encoding adiponectin.
Background. The prevalence of cardiovascular disease
(CVD) and inflammation is high in patients with end-stage re-
nal disease (ESRD). Adiponectin is an adipocytokine that may
have significant anti-inflammatory and anti-atherosclerotic ef-
fects. Low adiponectin levels have previously been found in
patients with high risk for CVD.
Methods. In a cohort of 204 (62% males) ESRD patients
aged 52 ± 1 years the following parameters were studied: pres-
ence of CVD, body composition, plasma adiponectin (N = 107),
cholesterol, triglycerides, HDL-cholesterol, serum leptin, high-
sensitivity C-reactive protein (hs-CRP), urinary albumin excre-
tion (UAE), and single-nucleotide polymorphisms (SNPs) in
the apM1 gene at positions –11391, –11377, 45, and 276. Thirty-
six age- (52 ± 2 years) and gender-matched (64% males) healthy
subjects served as control subjects.
Results. Markedly (P < 0.0001) elevated median plasma
adiponectin levels were observed in ESRD patients (22.2 lg/
mL), especially type 1 diabetic patients (36.8 lg/mL), compared
to control subjects (12.2 lg/mL). Log plasma adiponectin cor-
related to visceral fat mass (R = −0.29; P < 0.01) and Log hs-
CRP (R = −0.26; P < 0.01). In a stepwise (forward followed by
backward) multiple regression model only type-1 diabetes (P <
0.001) and visceral fat mass (P < 0.05) were independently as-
sociated with plasma adiponectin levels. The adiponectin gene
–11377 C/C genotype was associated with a lower prevalence of
CVD (25 vs. 42%) compared to the G/C genotype.
Conclusion. The present cross-sectional study demonstrates
that, whereas genetic variations seem to have a minor impact
on circulating adiponectin levels, lower visceral fat mass and
type 1 diabetes mellitus are associated with elevated plasma
adiponectin levels in ESRD patients. Furthermore, low levels
of adiponectin are associated with inflammation in ESRD.
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The life span of patients with end-stage renal disease
(ESRD) is reduced, and cardiovascular disease (CVD)
accounts for a premature death in more than 50% of pa-
tients from Western Europe and North America undergo-
ing regular dialysis [1]. The risk for CVD in a 30-year-old
ESRD patient is, in fact, similar to the calculated risk of a
70- to 80-year-old subject from the nonrenal population.
Although traditional risk factors, such as hypertension,
dyslipidemia, and diabetes mellitus may account for a
large portion of premature CVD in ESRD, much recent
interest has focused on nontraditional risk factors such as
inflammation and oxidative stress leading to endothelial
dysfunction [2]. Adipose tissue has recently been con-
sidered to be a hormonally active system that secretes
various proteins, such as leptin, interleukin (IL)-6, tumor
necrosis factor-a (TNF-a), resistin, plasminogen activa-
tor inhibitor, and adiponectin [3].
Adiponectin is a 30-kD adipocyte complement-related
protein encoded by the adipose most abundant gene tran-
script 1 (apM1), which is located in a diabetes suscepti-
bility locus on chromosome 3q27 [4]. Adiponectin acts
peripherally and circulates in human plasma at high lev-
els (about 0.01% of the total plasma protein pool) [5]. This
protein is thought to have significant anti-inflammatory,
insulin-sensitizing and anti-atherogenic effects [6, 7], and
seems to play a protective role in vascular injury, as it
modulates endothelial inflammatory response in vitro [6]
and inhibits endothelial nuclear factor kappa B (NF-jB)
signaling [8]. Recently, the cloning of two adiponectin
receptors that mediate antidiabetic metabolic effects was
reported [9]. Low plasma levels of adiponectin have been
documented in various nonrenal patient populations at
risk of CVD, such as in patients with dyslipidemia [10],
essential hypertension [11, 12], type 2 diabetes mellitus
(NIDDM) [13], obesity [14], and coronary artery disease
[15]. Conversely, both weight loss [16] and pharmacologic
treatment of insulin insensitivity by thiazolidinediones
[17] have been associated with increased adiponectin
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levels in nonrenal patient groups. Interestingly, Zocalli
et al [5] reported higher plasma adiponectin levels in
hemodialysis patients compared to healthy subjects. Al-
though this suggests that adiponectin accumulates in
ESRD, the role of body composition, type of diabetes, and
specific factors associated with renal dysfunction in the
metabolism of adiponectin has, to the best of our knowl-
edge, not previously been investigated in detail in ESRD
patients. Moreover, although recent data from nonrenal
patient populations suggest that genetic variations in the
apM1 gene are associated with both plasma adiponectin
levels and the clinical phenotype in various nonrenal pa-
tient populations, no data on the impact of genetic vari-
ations are yet available in ESRD patients. Because low
adiponectin has been shown to predict clinical outcome
in ESRD [5], we hypothesized that plasma adiponectin
levels may be associated with factors known or spec-
ulated to be associated with poor clinical outcome in
ESRD patients, such as residual renal function, diabetes
mellitus, inflammation, body composition, and genetic
predisposition.
The objective of the present study was, therefore, to
relate plasma levels of adiponectin in ESRD patients to
serum leptin, body composition (regional fat mass distri-
bution), inflammatory biomarkers (hs-CRP and fibrino-
gen), glomerular filtration rate (GFR), albuminuria, and
blood lipids. The impact of genetic polymorphisms within
apM1 gene on plasma adiponectin levels and clinical char-
acteristics were also studied.
METHODS
Patients
Two hundred and four ESRD patients (127 males) with
a mean age of 52 ± 1 years were evaluated shortly before
the beginning of renal replacement therapy (GFR 6.5 ±
0.2 mL/min). The patients were enrolled in an ongoing
prospective study on predialysis patients, the results of
which have been published in part elsewhere [18]. The
study exclusion criteria were age >70 years, overt infec-
tious complications and unwillingness to participate in
the study. The Ethics Committee of the Karolinska Insti-
tutet approved the study protocol at Huddinge University
Hospital, Stockholm, and informed consent was obtained
from patients and controls. Fifty-nine (29%) of the pa-
tients had diabetes mellitus, including 29 type 1 diabetic
patients, defined as insulin-dependent diabetes mellitus
(IDDM) from the onset of disease, and 30 type 2 dia-
betic patients, defined as initially non–insulin-dependent
diabetes mellitus (NIDDM). It is notable that accord-
ing to current therapeutic recommendations, most (N =
28) of the NIDDM patients had been switched to in-
sulin treatment following a period of peroral antidiabetic
treatment and/or diet. Sixty-three of the patients had a
clinical history of cerebrovascular, cardiovascular, and/or
peripheral vascular disease (grouped as CVD). Of the 63
patients, 14 had suffered from cerebrovascular disease
(stroke), 22 had one or more histories of acute myocar-
dial infarction, 30 had clinical signs of ischemic heart dis-
ease (angina pectoris) or had undergone coronary artery
bypass surgery, 21 had a history of peripheral ischemic
atherosclerotic vascular disease, and three patients had a
history of an aortic aneurysm. Mean systolic and diastolic
blood pressures at the time of investigation were 151 ± 2
and 89 ± 1 mm Hg, respectively. Most patients were on
antihypertensive medications as well as other commonly
used drugs in ESRD, such as phosphate and potassium-
binders, diuretics, and vitamin B, C, and D supplementa-
tion. None of the patients were on thiazolidinediones.
Two different control groups were studied. The con-
trol subjects for apM1 genotyping consisted of 209 unre-
lated Caucasians living in Stockholm County (62% males;
mean age, 40 ± 1 years), whereas the control group for
plasma adiponectin analysis consisted of 36 healthy sub-
jects (64% males; mean age, 52 ± 2 years).
Methods
After an overnight fast, venous blood samples
were taken for analysis of blood lipids (cholesterol,
triglycerides, HDL cholesterol), fibrinogen, plasma
adiponectin, serum leptin, HbA1c, serum albumin, and
high-sensitivity C-reactive protein (hs-CRP). The sam-
ples were kept frozen in –70◦C if not analyzed im-
mediately. Glomerular filtration rate (GFR) (corrected
for body surface area) estimated as the mean of urea
and creatinine clearance, and urinary albumin excre-
tion (UAE) were calculated from a 24-hour urinary
collection. Plasma adiponectin levels were measured
by a commercially available high-sensitivity photo-
metric enzyme-linked immunosorbent assay (ELISA)
(Boerhinger Mannheim, Mannheim, Germany). The low-
est level of human adiponectin detected by this assay is
1 ng/mL in a 100-lL sample size. The intra-assay varia-
tion is 2%–4% and inter-assay variation about 9%, de-
pending on the sample concentration. Serum leptin levels
were measured by a radioimmunoassay kit (Linco Re-
search, Inc., St. Charles, MO, USA) that is 100% specific
for human leptin with a sensitivity of 0.5 ng/mL. The test
utilizes 125I labeled human leptin and human leptin an-
tiserum to determine the level of total (free plus bound
to serum proteins) leptin in serum. Blood lipids, hs-CRP
(nephelometry), UAE, fibrinogen, HbA1c, and serum al-
bumin (bromcresol purple) were analyzed using routine
methods at the Department of Clinical Chemistry at Hud-
dinge University Hospital. Lean body mass and total fat
mass were estimated by dual energy x-ray absorptiometry
(DEXA) using the DPX-L device (Luna Corp., Madison,
WI, USA). Regional estimations of truncal, arm, and leg
fat mass were performed in 181 of the patients.
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Genotyping
A 5 mL EDTA sample of peripheral blood, from
which DNA was extracted using QIAampDNA kit, was
drawn. Samples were stored at −20◦C. Sequence ampli-
fication was performed by the polymerase chain reaction
(PCR) on a PTC-225 Thermocycler (MJ Research, Inc.,
Cambridge, MA, USA). PCR primers were designed
using the software Primer Designer 4 for Windows, ver-
sion 4.1 c© or as previously described [19], and one primer
in each primer pair was biotinylated. Genetic polymor-
phisms in the apM1 gene at positions –11391, −11377,
45, and 276 were analyzed by pyrosequencing analysis.
SNPs –11391 and –11377 are located in the promotor
region, whereas SNP 45 and 276 are located in exon 2
and intron 2, respectively. SNPs –11391 and –11377 were
amplified in a single fragment using forward primer 5′-
ACTTGCCCTGCCTCTGTCTG –3′ and reverse primer
5′-biotinGCCTGGAGAACTGGAAGCTG-3′. PCR
primers for SNP 45 were forward 5′-CTGTTGCTGGG
AGCTGTTC and reverse 5′-biotinGCCATCTCTGCC
ATCACGGCCT-3′ and for SNP 276 forward 5′-biotin
GGCCTCTTTCATCACAGACC-3′ and reverse 5′-AG
ATGCAGCAAAGCCAAAGT-3′ (GenBank accession
no. AB012163S2). Sequencing primers were placed ad-
jacent to the SNPs and were 5′-GTGGCTTGCAAGAA
CC-3′; 5′-GCTCAGATCCTGC-3′; 5′-TACTGCTATTA
GCTCTGCCCGG-3′ and 5′-TAGGCCTTAGTTAATA
ATGAATG-3′ for SNPs –11391, –11377, 45, and 276,
respectively. All oligonucleotides were synthesized by
Thermohybaid (Ulm, Germany). The PCR reaction
volume of 50 lL contained 20–50 ng of DNA, 10 pmol/L
of each forward and reverse primer, 0.2 mmol/L of
each dNTP, 0.3 U/L of DyNAzymeTM II (DNA Poly-
merase, Finnzymes, CA, USA), 10 mmol/L of Tris-HCl,
1.5 mmol/L of MgCl2, 50 mmol/L of KCl, and 0.1% Triton
X-100. The pyrosequencing reaction was performed on
a PSQ96TM Instrument from Pyrosequencing AB (Up-
psala, Sweden) as described previously [20]. Genepop
(http://wbiomed.curtin.edu.au/genepop/index.html) was
used to test the genotype distributions for Hardy-
Weinberg equilibrium. Linkage disequilibrium was
calculated according to Pak Sham in Statistics in Human
Genetics, pp. 151–157.
Statistical analysis
Results are expressed as mean values ± SEM, with
P < 0.05 indicating significance. As plasma adiponectin,
hs-CRP, UAE, and serum leptin levels were not nor-
mally distributed they are given as median and range.
They were log10-transformed before entering statistical
analysis. Comparisons between two groups were made
by two-sided unpaired Student t test. For comparisons
of continuous data between three groups the Kruskall-
Wallis analysis was used. Comparisons between groups
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Fig. 1. Plasma adiponectin levels in nondiabetic patients, type 1 and
type 2 diabetic patients and healthy control subjects.
for nominal variables were made by chi-square. Correla-
tions were performed by linear regression analysis and
stepwise (forward followed by backward) multiple re-
gression analysis. The statistical analysis was performed
using Statview c© version 5.00 for Windows (SAS Insti-
tiute, Inc., Berkley, CA, USA).
RESULTS
Median plasma adiponectin was significantly (P <
0.0001) elevated in ESRD patients (22.2 lg/mL) com-
pared to control patients (12.2 lg/mL) as shown in
Figure 1. Healthy females (14.1 lg/mL) had a signifi-
cantly (P < 0.05) higher median plasma adiponectin level
than healthy males (11.9 lg/mL). It should be emphasized
that plasma adiponectin was measured only in a subset
(N = 107) of the 204 ESRD patients. However, no sig-
nificant differences either in body composition, inflam-
matory markers, serum leptin, GFR, or UAE were noted
between the 107 patients in whom plasma adiponectin
was measured and the 97 patients in whom it was not
(data not shown). As expected, male ESRD patients had
a higher lean body mass (55.9 ± 0.7 vs. 39.7 ± 0.8 kg; P <
0.0001) but lower total fat mass (20.0 ± 0.7 vs. 24.4 ±
1.3 kg; P < 0.01) compared to female ESRD patients.
No difference in truncal fat mass was observed between
males and females. Whereas no significant differences in
median hs-CRP, median plasma adiponectin, and triglyc-
eride levels were noted between the two sexes, the female
ESRD patients had significantly higher total cholesterol
(6.0 ± 0.2 vs. 5.4 ± 0.1 mmol/L; P < 0.01), HDL choles-
terol (1.3±0.1 vs. 1.1±0.1 mmol/L; P <0.01), and median
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Table 1. Clinical data, body composition, renal function, blood lipids, inflammatory biomarkers, and distribution of apM1 genotypes in
nondiabetic, type 1 and type 2 diabetic patients, respectively
Nondiabetes Type 1 DM Type 2 DM Significance
Clinical data N = 145 N = 29 N = 30
Age years 51 ± 1 46 ± 2 61 ± 1 P < 0.0001
Males % 59 62 77 NS
Cardiovascular disease % 20 38 77 P < 0.0001
HbA1c % 5.0 ± 0.1 7.5 ± 0.4 5.9 ± 0.2 P < 0.0001
Body composition
Body mass index kg/m2 24.4 ± 0.4 25.1 ± 4.8 27.5 ± 4.1 P < 0.01
Total body fat mass kga 21.2 ± 0.8 20.9 ± 1.6 23.9 ± 1.5 NS
Truncal fat mass kga 11.4 ± 0.5 11.0 ± 0.9 13.9 ± 1.0 P = 0.08
Arm fat mass kga 2.8 ± 0.2 2.6 ± 0.3 2.9 ± 0.2 NS
Leg fat mass kga 5.9 ± 0.3 6.1 ± 0.5 5.7 ± 0.5 NS
Lean body mass kga 48.9 ± 0.9 51.6 ± 2.1 53.7 ± 1.8 NS
S-leptin ng/mLb,g 13.0 (1.1–204.0) 10.3 (1.7–83.0) 19.0 (3.2–92.0) P = 0.07
P-adiponectin lg/mLc,g 17.6 (3.9–74.7) 36.8 (19.2–74.7) 20.0 (6.9–59.8) P < 0.01
Renal function
GFR mL/min/1.73m2d 6.4 ± 0.2 6.8 ± 0.5 6.4 ± 0.4 NS
UAE mg/24 he,g 2019 (52–9580) 3766 (375–11315) 2626 (886–11808) P < 0.05
Blood lipids
Total cholesterol mmol/L 5.7 ± 0.1 5.8 ± 0.3 5.3 ± 0.2 NS
Triglycerides mmol/L 2.2 ± 0.1 2.3 ± 0.3 1.9 ± 0.2 NS
HDL-cholesterol mmol/L 1.2 ± 0.1 1.3 ± 0.1 1.1 ± 0.1 P < 0.05
Inflammatory biomarkers
S-albumin g/L 33.8 ± 0.5 31.1 ± 1.0 30.5 ± 1.1 NS
Fibrinogen g/L 5.0 ± 0.1 4.9 ± 0.2 5.6 ± 0.3 NS
hs-CRP mg/Lf,g 6.7 (0.2–105.0) 2.2 (0.2–136.0) 13.0 (0.3–163.0) P < 0.05
apM1 genotypes
apM1 −11391 (GG/GA/AA) 131/10/4 23/6/0 27/3/0 NS
apM1 −11377 (GG/GC/CC) 10/49/86 2/11/16 1/14/15 NS
apM1 45 (GG/GT/TT) 5/23/117 0/6/23 0/7/23 NS
apM1 276 (GG/GT/TT) 71/63/11 13/13/3 16/9/5 NS
Mean ± SEM indicated. GFR, glomerular filtration rate; UAE, urinary albumin excretion.
aN = 181; bN = 173; cN = 107; dN = 178; eN = 164; fN = 173; gmedian and range.
serum leptin (24.0 vs. 9.0 ng/mL; P < 0.0001), but lower
median UAE (1765 vs. 2707 mg/24h; P < 0.001) compared
to the males.
Demographic and clinical data of the study popu-
lation with regard to diabetic status are presented in
Table 1. Seventeen IDDM patients (36.8 lg/mL) had sig-
nificantly higher median plasma adiponectin level than
71 nondiabetic patients (17.6 lg/mL) and 19 NIDDM
(20.0 lg/mL) patients (Fig. 1). No difference in median
plasma adiponectin levels was noted comparing 70 pa-
tients without a history of CVD (22.8 lg/mL) and 37 pa-
tients with a history of CVD (20.2 lg/mL). In the whole
study population no significant correlations were noted
between log UAE and total cholesterol (R = 0.03), HDL
cholesterol (R = 0.04), and triglycerides (R = 0.10), re-
spectively, whereas log UAE correlated significantly to
serum albumin (R = −0.42; P < 0.0001), lean body mass
(R = 0.32; P < 0.0001), body fat mass (R = −0.17; P <
0.05), and Log hs-CRP (R = −0.17; P < 0.05).
In the whole study population, significant negative cor-
relations were observed between log plasma adiponectin
and total body fat mass (R = −0.22; P < 0.05), truncal
fat mass (R = −0.29; P < 0.01), lean body mass (R =
−0.26; P < 0.05), HbA1c (R = −0.21; P < 0.05) and log
serum leptin (R = −0.23; P < 0.05). The correlation be-
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Fig. 2. Correlation between truncal (visceral) fat mass (by DEXA) and
log plasma adiponectin levels in patients with end-stage renal disease.
tween log plasma adiponectin and truncal (visceral) fat
mass is shown in Figure 2. Conversely, no correlations
were observed between plasma adiponectin and arm and
leg (R = −0.11 and −0.08, respectively) fat mass. Log
plasma adiponectin correlated with levels of triglycerides
(R = −0.25; P < 0.05) and HDL cholesterol (R = 0.35;
P < 0.001) levels, whereas no significant correlation
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Fig. 3. Correlations between log hs-CRP and log plasma adiponectin (left) and fibrinogen and log plasma adiponectin (right) in patients with
end-stage renal disease.
(R = 0.14) was observed between log plasma adiponectin
and total cholesterol. Significant negative correlations
were noted between log plasma adiponectin and the in-
flammatory biomarkers fibrinogen (R = −0.23; P < 0.05;
N = 95) and log hs-CRP (R = −0.26; P < 0.01; N = 99),
as shown in Figure 3. A stepwise multiple regression
model analysis (N = 67) of log hs-CRP, correcting for
the impact of age, gender, diabetes mellitus, and truncal
fat mass, revealed an independent inverse relationship
(F-ratio 6.6; P <0.05) between log hs-CRP and log plasma
adiponectin.
Whereas no significant correlations were observed be-
tween log plasma adiponectin and age and GFR (R =
0.04 and R = −0.08, respectively), near significant corre-
lations were noted between log plasma adiponectin and
log UAE (R = 0.20; P = 0.07) and serum albumin (R =
−0.18; P = 0.06). In a stepwise multiple regression model
(N = 72), including UAE, gender, IDDM, visceral fat
mass, age, and the four apM1 SNPs, only the presence
of IDDM (F-ratio 13.7; P < 0.001) and visceral fat mass
(F-ratio 4.3; P < 0.05) were significantly associated with
log adiponectin plasma levels. When IDDM was re-
placed by NIDDM in another stepwise multiple regres-
sion model the association between plasma adiponectin
and diabetes was lost.
No differences in the genotype distribution of the four
apM1 SNPs at position –11391, −11377, 45, and 276 were
noted between the 204 ESRD patients and the 209 control
subjects. The genotype distribution was in Hardy Wein-
berg equilibrium for all SNPs in the control group. In
the patient group, however, the genotype distribution for
SNP –11391 deviated from Hardy Weinberg equilibrium
(P < 0.01, chi-square = 13.4). SNPs –11391, –11377, 45,
and 276 were in total linkage disequilibrium (LD)
(D′ ≥ 0.999) in both patients and control subjects. To-
tal LD also existed in both patients and controls between
SNPs –11391 and 276 (D′ = 0.60 and 0.56, respectively).
In the patient group there was LD between SNPs –11377
and 276 (D′ = 0.68) and among control subjects close to
LD (D′ = 0.49). However, in both patients and control
subjects, SNPs –11377 and 45, as well as SNPs –11391
and 45, were not in LD (D <0.317). No difference in
the genotype distribution of the four SNPs was noted
between males and females, or between nondiabetics,
IDDM, and NIDDM patients (Table 1). Table 2 shows
age, the prevalence of CVD, and inflammation (CRP ≥
10 mg/L) in ESRD patients according to apM1 genotype.
Whereas no significant differences were noted among
groups for apM1 45, 276, and –11391 genotypes, patients
with the apM1 –11377 G/C genotype had a significantly
(P < 0.05) higher prevalence of CVD compared to C/C
patients. Moreover, whereas no difference in blood lipid
levels were observed between the apM1 45, 276, and
–11391 genotypes, patients with the apM1 –11377 C/C
genotype did have lower triglyceride levels compared to
both G/G (P < 0.01) and G/C (P < 0.05) genotypes. More-
over, whereas no difference in plasma adiponectin levels
was noted between the apM1 45, −11377, and –11391
genotypes, 7 patients with the apM1 276 T/T genotype had
significantly (P <0.05) higher median plasma adiponectin
levels (Table 2). No significant differences in body com-
position (BMI, lean body mass, total fat mass, truncal fat
mass, arm and leg fat mass) were observed between the
different genotypes for any of the SNPs (data not shown).
DISCUSSION
In the present cross-sectional study of predialysis
patients we demonstrate elevated adiponectin levels
and significant relationships between elevated plasma
adiponectin and type 1 diabetes and visceral fat mass
content. On the other hand, genetic variations in the
apM1 gene seem to have only a minor impact on circu-
lating adiponectin levels in this patient group. Whereas
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Table 2. Age, plasma adiponectin, blood lipid levels, and prevalence
of cardiovascular disease and inflammation (CRP ≥10 mg/L) in four
different apM1 genotypes
apM1 45 G/G (N = 5) G/T (N = 36) T/T (N = 163)
Age years 61 ± 4 54 ± 2 51 ± 1
P-adiponectin 22.8 (16.7–72.8) 24.4 (3.9–56.5) 21.2 (4.2–74.7)
lg/mLa,b
S-cholesterol 5.4 ± 0.8 5.5 ± 0.2 5.7 ± 0.1
mmol/L
Triglycerides 1.8 ± 0.2 2.2 ± 0.2 2.2 ± 0.1
mmol/L
HDL cholesterol 1.4 ± 0.3 1.2 ± 0.1 1.2 ± 0.1
mmol/L
Cardiovascular 40 47 27
disease %
Inflammation % 60 44 33
apM1 276 G/G (N = 100) G/T (N = 85) T/T (N = 19)
Age years 53 ± 1 51 ± 1 52 ± 3
P-adiponectin 22.8 (16.7–74.9) 19.2 (4.2–64.8) 42.5 (12.8–64.2)f
lg/mLa,c
S-cholesterol 5.7 ± 0.2 5.5 ± 0.1 5.7 ± 0.4
mmol/L
Triglycerides 2.3 ± 0.1 2.1 ± 0.1 2.0 ± 0.2
mmol/L
HDL cholesterol 1.2 ± 0.1 1.2 ± 0.1 1.1 ± 0.1
mmol/L
Cardiovascular 38 24 26
disease %
Inflammation % 42 28 37
apM1 −11377 G/G (N = 13) G/C (N = 74) C/C (N = 117)
Age years 52 ± 1 53 ± 2 50 ± 3
P-adiponectin 26.1 (6.1–49.8) 21.1 (5.0–72.8) 22.8 (3.9–74.7)
lg/mLa,d
S-cholesterol 5.6 ± 0.3 5.5 ± 0.2 5.7 ± 0.1
mmol/L
Triglycerides 2.9 ± 0.5 2.4 ± 0.2 2.0 ± 0.1g,h
mmol/L
HDL cholesterol 1.2 ± 0.2 1.2 ± 0.1 1.2 ± 0.1
mmol/L
Cardiovascular 23 42 25i
disease %
Inflammation % 46 41 32
apM1 −11391 G/G (N = 181) G/A (N = 19) A/A (N = 4)
Age years 51 ± 1 51 ± 3 52 ± 1
P-adiponectin 21.9 (4.2–74.7) 27.6 (3.9–58.3) 14.6 and 42.5
lg/mLa,e
S-cholesterol 5.7 ± 0.1 5.1 ± 0.3 4.8 ± 0.7
mmol/L
Triglycerides 2.2 ± 0.1 1.8 ± 0.2 2.7 ± 1.1
mmol/L
HDL cholesterol 1.2 ± 0.1 1.2 ± 0.1 1.1 ± 0.2
mmol/L
Cardiovascular 31 32 25
disease %
Inflammation % 34 47 50
aMedian and range; bN = 3 (G/G), N = 22 (G/T), and N = 82 (T/T); cN = 55
(G/G), N = 45 (G/T), and N = 7 (T/T); dN = 7 (G/G), N = 43 (G/C), and N = 57
(C/C); eN = 94 (G/G), N = 11 (G/A), and N = 2 (A/A); fP < 0.05 vs. G/G and
G/T; gP < 0.05 vs. G/C; hP < 0.01 vs. G/G; iP < 0.05 vs. G/C.
hypoadiponectinaemia has been demonstrated for sev-
eral other groups of patients with increased risk for
CVD, such as patients with dyslipidemia [10], essen-
tial hypertension [12], NIDDM [13], obesity [14], and
coronary artery disease [15], the present study demon-
strates markedly elevated plasma adiponectin levels in
ESRD patients. Thus, our results confirm those recently
reported by Zoccali et al [5], who found markedly el-
evated adiponectin levels in a group of ESRD patients
treated by hemodialysis (HD). The reason(s) why ESRD
patients have elevated levels of plasma adiponectin are
not evident.
The present study demonstrates significant relation-
ships between plasma adiponectin levels and body
composition in ESRD patients. Although no significant
correlations were observed between adiponectin and
BMI, arm and leg fat mass, significant negative corre-
lations were observed between adiponectin and both
total and truncal fat mass. Interestingly, the best corre-
lation was observed between the adiponectin level and
the truncal (i.e., visceral) fat mass (Fig. 2), the fat tis-
sue depot considered to be the most metabolically active
and which has been identified as a key factor in the de-
velopment of insulin resistance, NIDDM, and premature
atherosclerosis [21]. Our finding is in agreement with a
recent study by Cnop et al [22] in 182 nonrenal subjects,
demonstrating that adiponectin levels are determined to
a large extent by the intra-abdominal fat mass. It is of in-
terest that recent findings suggest that abdominal visceral
and subcutaneous fat mass is fundamentally different in
function. Indeed, in a recent study, marked differences in
the expression of 1660 genes between visceral and subcu-
taneous fat tissue were noted, suggesting that these two
adipose tissue depots are biologically distinct [23].
An unexpected finding of the present study was that pa-
tients with IDDM had significantly elevated adiponectin
levels compared to both nondiabetic and NIDDM pa-
tients (Fig. 1). Interestingly, a previous letter by Ima-
gawa et al [24] also reported elevated plasma adiponectin
levels in a group of IDDM patients, but without re-
nal failure. The reasons why IDDM patients have
elevated adiponectin levels compared to NIDDM pa-
tients are not evident. Although albuminuria recently
was reported to be associated with elevated adiponectin
levels [25], it should be noted that the significant asso-
ciation between IDDM and adiponectin prevailed, even
after correcting for UAE. Moreover, as visceral fat mass
tended to be higher in NIDDM, a difference in body
composition may be another reason why IDDM have
higher adiponectin levels. However, the significant as-
sociation between plasma adiponectin and IDDM pre-
vailed following the correction for the impact of visceral
fat mass. As adiponectin may be an important selectively
controlled modulator of insulin sensitivity [26], it could
be speculated that insulin deficiency may contribute to
elevated level of adiponectin in IDDM. However, as it
has been reported that insulin therapy did not change
adiponectin levels [24], and circulating adiponectin lev-
els do not change after the onset of diabetes in mice,
although insulin levels dramatically decreased [27], it can-
not be ruled out that factors other than glucose and in-
sulin levels may also control adiponectin levels in IDDM.
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Clearly, as our study demonstrates a higher prevalence of
inflammation in NIDDM than IDDM patients, the puta-
tive anti-inflammatory role of adiponectin in this scenario
is worthy of further evaluation.
In the present study, significant negative correlations
were found between adiponectin and two biomarkers
of inflammation, hs-CRP and fibrinogen (Fig. 3). Im-
portantly, the inverse correlation of adiponectin and
hs-CRP remained statistically significant even after ad-
justment for confounders. Thus, our data suggest that
hypoadiponectinaemia may also serve as a marker of
increased inflammatory status in ESRD patients. Our
results confirm those recently presented by Ouchi et al
[28] in a group of 101 male patients, of whom a ma-
jority had coronary atherosclerosis, showing a recipro-
cal association of adiponectin and CRP levels in human
plasma. Also, other recent studies show interactions be-
tween inflammatory parameters and plasma adiponectin
[29, 30]. Indeed, it has been suggested that adiponectin
may play a role in modulating the inflammatory response
by inhibition of the expression of adhesion molecules
on endothelial cells [6], suppressing macrophage func-
tion [31] and inhibiting NF-jB signaling [8]. It is also
believed that adiponectin has anti-inflammatory proper-
ties and can counteract the pro-inflammatory effects of
TNF-a [6], a pro-inflammatory cytokine, which might in-
fluence the production of IL-6 and CRP. A beneficial anti-
inflammatory role of adiponectin is further supported by
in vivo studies showing that adiponectin prevented neoin-
timal formation [32] and atherosclerosis [33] in mice.
One aim of the present study was to determine the rela-
tionship between variations of the apM1 gene on plasma
levels of adiponectin and the clinical phenotype in ESRD
patients. Whereas our results suggest that the apM1 45,
276, and –11391 genotypes do not influence the clinical
phenotype of this patient group, the present results sug-
gest that the apM1 –11377 C/C genotype is associated
with both lower triglyceride levels and a lower preva-
lence of CVD compared to the other genotypes. Thus,
further studies are needed to demonstrate if this specific
genotype is associated with a survival advantage in ESRD
patients. Our findings also suggest that genetic variations
of the adiponectin gene do not have a major impact on
plasma adiponectin levels in ESRD. Indeed, although pa-
tients with the relatively rare T/T apM1 276 genotype
had significantly higher plasma adiponectin levels than
the other genotypes, no significant differences in plasma
adiponectin levels were noted for any of the other poly-
morphisms in this patient group. This finding is in agree-
ment with data by Menzaghi et al [34] from 413 non-
diabetic individuals showing significantly lower plasma
levels of adiponectin in apM1 276 G/G homozygotes.
Some limitations of the present study should also be
considered. First, as plasma adiponectin levels were not
available in all patients, larger patient groups are needed
to confirm the observed relationships. However, no dif-
ferences in either body composition, prevalence of in-
flammation, or renal function were noted between the
patients in which adiponectin was measured and the
group of patients in which it was not. Second, as
C-peptide levels were not assessed at the time of diag-
nosis of diabetes mellitus the distinction between IDDM
and NIDDM was based only on clinical records. Although
the classification between the two types of diabetes was
easy in most cases, we cannot exclude that some of the
diabetic patients were misclassified. Third, as the classi-
fication of CVD was made only on the basis of clinically
manifest events, the true prevalence of atherosclerotic
vascular disease may have been underestimated [2].
Finally, it should be pointed out that this is a post hoc
analysis, which may limit the value of the study.
CONCLUSION
The present cross-sectional study confirms markedly
elevated levels of plasma adiponectin in ESRD pa-
tients. Whereas genetic variations in the genes encoding
adiponectin seem to have a minor impact on both plasma
adiponectin levels and clinical characteristics, the present
study shows that lower visceral fat mass and the presence
of IDDM both are independently associated with ele-
vated plasma adiponectin levels in patients with ESRD.
The present study also demonstrates that low levels of
adiponectin are associated with inflammation in ESRD.
Thus, further studies are needed to elucidate the poten-
tial anti-inflammatory and anti-atherosclerotic roles of
elevated adiponectin levels in the uremic milieu.
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